|
Re: Pointing in the right direction & bogus Lilly
|
3
|
Resverlogix Corp.
|
Dec 01, 2018 03:27PM
|
|
Re: Pointing in the right direction & bogus Lilly
|
4
|
Resverlogix Corp.
|
Dec 01, 2018 03:41PM
|
|
Re: Pointing in the right direction & bogus Lilly
|
1
|
Resverlogix Corp.
|
Dec 01, 2018 04:29PM
|
|
Re: Pointing in the right direction & bogus Lilly
|
1
|
Resverlogix Corp.
|
Dec 01, 2018 04:40PM
|
|
Re: Patient Enrollment Modeling
|
3
|
Resverlogix Corp.
|
Dec 01, 2018 08:33PM
|
|
Re: Patient Enrollment Modeling
|
2
|
Resverlogix Corp.
|
Dec 01, 2018 09:03PM
|
|
Re: Pointing in the right direction & bogus Lilly
|
3
|
Resverlogix Corp.
|
Dec 01, 2018 09:22PM
|
|
Re: Patient Enrollment Modeling
|
4
|
Resverlogix Corp.
|
Dec 02, 2018 08:07AM
|
|
Re: Patient Enrollment Modeling
|
1
|
Resverlogix Corp.
|
Dec 02, 2018 09:32AM
|
|
Re: Patient Enrollment Modeling
|
2
|
Resverlogix Corp.
|
Dec 02, 2018 05:44PM
|
|
Rationale and Design of Apabetalone BETonMACE Trial
|
3
|
Resverlogix Corp.
|
Dec 03, 2018 03:32PM
|
|
Re: Rationale and Design of Apabetalone BETonMACE Trial
|
5
|
Resverlogix Corp.
|
Dec 03, 2018 03:42PM
|
|
Re: Rationale and Design of Apabetalone BETonMACE Trial
|
3
|
Resverlogix Corp.
|
Dec 03, 2018 04:03PM
|
|
Re: Rationale and Design of Apabetalone BETonMACE Trial
|
5
|
Resverlogix Corp.
|
Dec 03, 2018 10:25PM
|
|
Re: Rationale and Design of Apabetalone BETonMACE Trial
|
2
|
Resverlogix Corp.
|
Dec 04, 2018 09:44AM
|
|
Re: Are statins overprescribed? Why the risks and benefits are so complex
|
2
|
Resverlogix Corp.
|
Dec 04, 2018 11:00AM
|
|
Re: Patient Enrollment Modeling
|
2
|
Resverlogix Corp.
|
Dec 04, 2018 01:20PM
|
|
Re: Are statins overprescribed? Why the risks and benefits are so complex
|
3
|
Resverlogix Corp.
|
Dec 04, 2018 01:35PM
|
|
Re: Are statins overprescribed? Why the risks and benefits are so complex
|
3
|
Resverlogix Corp.
|
Dec 04, 2018 04:25PM
|
|
Re: Are statins overprescribed? Why the risks and benefits are so complex
|
3
|
Resverlogix Corp.
|
Dec 04, 2018 08:04PM
|
